Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.

Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.

Tech Launch Arizona has crossed the milestone of 100 spinouts in its portfolio after achieving a new annual record in the 2019-2020 fiscal year.

Cerevel Therapeutics, co-founded by Pfizer, is set to undertake a reverse merger with Nasdaq-listed Arya II in a deal that will give Cerevel a market cap of $1.3bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU and backed by Exact Sciences and Blue Cross and Blue Shield Association, has raised $257m in series B funding.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.

Mount Sinai Health System spinoff Sema4 has achieved a valuation of more than $1bn following a $121m series C round that featured all existing external shareholders.

Heal has entered into a strategic partnership with Humana that includes a $100m investment from the corporate and will support an expansion into additional US cities.